Modulation of inflammasome-mediated pulmonary immune activation by type I IFNs protects bone marrow homeostasis during systemic responses to Pneumocystis lung infection

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3884-3895

  Searles, Steve ^a   Gauss, Katherine ^b   Wilkison, Michelle ^c   Hoyt, Teri R ^c   Dobrinen, Erin ^c   Meissner, Nicole ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Montana Veterinary Diagnostic Laboratory   (United States)

^c MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYTOKINE; GAMMA INTERFERON; INFLAMMASOME; INTERFERON; INTERFERON RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; REGULATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW DEPRESSION; CELL STRESS; CYTOKINE RESPONSE; ENZYME ACTIVATION; HEMATOPOIESIS; IMMUNOCOMPETENCE; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MOUSE; NEUTROPHIL; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL TIME; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW; CASPASE 1; DISEASE MODELS, ANIMAL; GENE KNOCKOUT TECHNIQUES; HOMEOSTASIS; INFLAMMASOMES; INTERFERON TYPE I; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-18; LYMPHOCYTES; MICE; MICE, KNOCKOUT; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 84885099926     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301344     Document Type: Article

References (110)

1. Leguit, R. J., and J. G. van den Tweel. 2010. The pathology of bone marrow failure. Histopathology 57:655-670.
2. Young, N. S., R. T. Calado, and P. Scheinberg. 2006. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108:2509-2519.
3. Bagby, G. C., J. M. Lipton, E. M. Sloand, and C. A. Schiffer. 2004. Marrow failure. Hematology (Am Soc Hematol Educ Program) 2004:318-336.
4. Bijangi-Vishehsaraei, K., M. R. Saadatzadeh, A. Werne, K. A. McKenzie, R. Kapur, H. Ichijo, and L. S. Haneline. 2005. Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1. Blood 106:4124-4130.
5. Du, W., Z. Adam, R. Rani, X. Zhang, and Q. Pang. 2008. Oxidative stress in Fanconi anemia hematopoiesis and disease progression. Antioxid. Redox Signal. 10:1909-1921.
6. Zheng, P., X. Chang, Q. Lu, and Y. Liu. 2013. Cytopenia and autoimmune diseases: a vicious cycle fueled by mTOR dysregulation in hematopoietic stem cells. J. Autoimmun. 41:182-187.
7. Isgrò, A., A. Aiuti, W. Leti, C. Gramiccioni, A. Esposito, I. Mezzaroma, and F. Aiuti. 2005. Immunodysregulation of HIV disease at bone marrow level. Autoimmun. Rev. 4:486-490.
8. Isgrò, A., A. Aiuti, I. Mezzaroma, L. Ruco, M. Pinti, A. Cossarizza, and F. Aiuti. 2005. HIV type 1 protease inhibitors enhance bone marrow progenitor cell activity in normal subjects and in HIV type 1-infected patients. AIDS Res. Hum. Retroviruses 21:51-57.
9. Thomas, C. F., Jr., and A. H. Limper. 2004. Pneumocystis pneumonia. N. Engl. J. Med. 350:2487-2498.
10. Morris, A., K. Wei, K. Afshar, and L. Huang. 2008. Epidemiology and clinical significance of pneumocystis colonization. J. Infect. Dis. 197:10-17.
11. Morris, A., M. Netravali, H. M. Kling, T. Shipley, T. Ross, F. C. Sciurba, and K. A. Norris. 2008. Relationship of pneumocystis antibody response to severity of chronic obstructive pulmonary disease. Clin. Infect. Dis. 47:e64-e68.
12. Biskobing, D. M. 2002. COPD and osteoporosis. Chest 121:609-620.
13. Harmsen, A. G., and M. Stankiewicz. 1990. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J. Exp. Med. 172:937-945.
14. Shellito, J., V. V. Suzara, W. Blumenfeld, J. M. Beck, H. J. Steger, and T. H. Ermak. 1990. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J. Clin. Invest. 85:1686-1693.
15. Romani, L. 2011. Immunity to fungal infections. Nat. Rev. Immunol. 11:275-288.
16. Joly, S., and F. S. Sutterwala. 2010. Fungal pathogen recognition by the NLRP3 inflammasome. Virulence 1:276-280.
17. Lund, F. E., K. Schuer, M. Hollifield, T. D. Randall, and B. A. Garvy. 2003. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody. J. Immunol. 171:1423-1430.
18. Meissner, N. N., S. Swain, M. Tighe, A. Harmsen, and A. Harmsen. 2005. Role of type I IFNs in pulmonary complications of Pneumocystis murina infection. J. Immunol. 174:5462-5471.
19. Swain, S. D., N. Meissner, S. Han, and A. Harmsen. 2011. Pneumocystis infection in an immunocompetent host can promote collateral sensitization to respiratory antigens. Infect. Immun. 79:1905-1914.
20. Nelson, M. P., B. S. Christmann, J. L. Werner, A. E. Metz, J. L. Trevor, C. A. Lowell, and C. Steele. 2011. IL-33 and M2a alveolar macrophages promote lung defense against the atypical fungal pathogen Pneumocystis murina. J. Immunol. 186:2372-2381.
21. Wang, J., F. Gigliotti, S. P. Bhagwat, T. C. George, and T. W. Wright. 2010. Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia. PLoS Pathog. 6:e1001058.
22. Gigliotti, F., C. G. Haidaris, T. W. Wright, and A. G. Harmsen. 2002. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect. Immun. 70:1069-1074.
23. Levy, D. E., I. J. Marié, and J. E. Durbin. 2011. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol 1:476-486.
24. Bogdan, C., J. Mattner, and U. Schleicher. 2004. The role of type I interferons in non-viral infections. Immunol. Rev. 202:33-48.
25. Ramirez-Ortiz, Z. G., C. K. Lee, J. P. Wang, L. Boon, C. A. Specht, and S. M. Levitz. 2011. A nonredundant role for plasmacytoid dendritic cells in host defense against the human fungal pathogen Aspergillus fumigatus. Cell Host Microbe 9:415-424.
26. Platanias, L. C. 2005. Mechanisms of type-I-and type-II-interferon- mediated signalling. Nat. Rev. Immunol. 5:375-386.
27. Stetson, D. B., and R. Medzhitov. 2006. Type I interferons in host defense. Immunity 25:373-381.
28. de Waal Malefyt, R. 1997. The role of type I interferons in the differentiation and function of Th1 and Th2 cells. Semin. Oncol. 24:S9-94-S99-98.
29. Jego, G., A. K. Palucka, J. P. Blanck, C. Chalouni, V. Pascual, and J. Banchereau. 2003. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19:225-234.
30. Xin, L., D. A. Vargas-Inchaustegui, S. S. Raimer, B. C. Kelly, J. Hu, L. Zhu, J. Sun, and L. Soong. 2010. Type I IFN receptor regulates neutrophil functions and innate immunity to Leishmania parasites. J. Immunol. 184:7047-7056.
31. Banchereau, J., and V. Pascual. 2006. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25:383-392.
32. Pascual, V., L. Farkas, and J. Banchereau. 2006. Systemic lupus erythematosus: all roads lead to type I interferons. Curr. Opin. Immunol. 18:676-682.
33. Chang, E. Y., B. Guo, S. E. Doyle, and G. Cheng. 2007. Cutting edge: involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL-10 production. J. Immunol. 178:6705-6709.
34. Guo, B., E. Y. Chang, and G. Cheng. 2008. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118:1680-1690.
35. Levings, M. K., R. Sangregorio, F. Galbiati, S. Squadrone, R. de Waal Malefyt, and M. G. Roncarolo. 2001. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. 166:5530-5539.
36. Sharif, M. N., D. Sosic, C. V. Rothlin, E. Kelly, G. Lemke, E. N. Olson, and L. B. Ivashkiv. 2006. Twist mediates suppression of inflammation by type I IFNs and Axl. J. Exp. Med. 203:1891-1901.
37. Guarda, G., M. Braun, F. Staehli, A. Tardivel, C. Mattmann, I. Förster, M. Farlik, T. Decker, R. A. Du Pasquier, P. Romero, and J. Tschopp. 2011. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34:213-223.
38. Barbero, P., M. Bergui, E. Versino, A. Ricci, J. J. Zhong, B. Ferrero, M. Clerico, A. Pipieri, E. Verdun, L. Giordano, and L. Durelli; INCOMIN Trial Study Group. 2006. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. Mult. Scler. 12:72-76.
39. Clerico, M., F. Faggiano, J. Palace, G. Rice, M. Tintorè, and L. Durelli. 2008. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst. Rev. 2: CD005278.
40. Durelli, L., P. Barbero, and M. Clerico; INCOMIN Trial Study Group. 2006. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 67:2264, author reply 2264-2265.
41. Madsen, S. M., P. Schlichting, B. Davidsen, O. H. Nielsen, B. Federspiel, P. Riis, and P. Munkholm. 2001. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of leftsided ulcerative colitis. Am. J. Gastroenterol. 96:1807-1815.
42. Wirtz, S., and M. F. Neurath. 2005. Illuminating the role of type I IFNs in colitis. J. Clin. Invest. 115:586-588.
43. Atreya, R., J. Mudter, S. Finotto, J. Müllberg, T. Jostock, S. Wirtz, M. Schütz, B. Bartsch, M. Holtmann, C. Becker, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6:583-588.
44. Gough, D. J., N. L. Messina, C. J. Clarke, R. W. Johnstone, and D. E. Levy. 2012. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36:166-174.
45. Kirkwood, J. M., C. Bender, S. Agarwala, A. Tarhini, J. Shipe-Spotloe, B. Smelko, S. Donnelly, and L. Stover. 2002. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J. Clin. Oncol. 20:3703-3718.
46. Schmitt, K., B. C. Hompesch, K. Oeland, W. G. von Staehr, and P. A. Thürmann. 1999. Autoimmune thyroiditis and myelosuppression following treatment with interferon-alpha for hepatitis C. Int. J. Clin. Pharmacol. Ther. 37:165-167.
47. Sakamoto, E., F. Hato, T. Kato, C. Sakamoto, M. Akahori, M. Hino, and S. Kitagawa. 2005. Type I and type II interferons delay human neutrophil apoptosis via activation of STAT3 and up-regulation of cellular inhibitor of apoptosis 2. J. Leukoc. Biol. 78:301-309.
48. David, J. P. 2007. Osteoimmunology: a view from the bone. Adv. Immunol. 95:149-165.
49. Takayanagi, H. 2005. Inflammatory bone destruction and osteoimmunology. J. Periodontal Res. 40:287-293.
50. Aguila, H. L., and D. W. Rowe. 2005. Skeletal development, bone remodeling, and hematopoiesis. Immunol. Rev. 208:7-18.
51. Adams, G. B., and D. T. Scadden. 2006. The hematopoietic stem cell in its place. Nat. Immunol. 7:333-337.
52. Essers, M. A., S. Offner, W. E. Blanco-Bose, Z. Waibler, U. Kalinke, M. A. Duchosal, and A. Trumpp. 2009. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458:904-908.
53. Hosmalin, A., and P. Lebon. 2006. Type I interferon production in HIV-infected patients. J. Leukoc. Biol. 80:984-993.
54. Sivaraman, V., L. Zhang, and L. Su. 2011. Type I interferon contributes to CD4 + T cell depletion induced by infection with HIV-1 in the human thymus. J. Virol. 85:9243-9246.
55. Pacanowski, J., L. Develioglu, I. Kamga, M. Sinet, M. Desvarieux, P. M. Girard, and A. Hosmalin. 2004. Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection. J. Infect. Dis. 190:1889-1892.
56. Pacanowski, J., S. Kahi, M. Baillet, P. Lebon, C. Deveau, C. Goujard, L. Meyer, E. Oksenhendler, M. Sinet, and A. Hosmalin. 2001. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 98:3016-3021.
57. Chehimi, J., D. E. Campbell, L. Azzoni, D. Bacheller, E. Papasavvas, G. Jerandi, K. Mounzer, J. Kostman, G. Trinchieri, and L. J. Montaner. 2002. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J. Immunol. 168:4796-4801.
58. Siegal, F. P., P. Fitzgerald-Bocarsly, B. K. Holland, and M. Shodell. 2001. Interferon-alpha generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection. AIDS 15:1603-1612.
59. Fitzgerald-Bocarsly, P., and E. S. Jacobs. 2010. Plasmacytoid dendritic cells in HIV infection: striking a delicate balance. J. Leukoc. Biol. 87:609-620.
60. Meissner, N., M. Rutkowski, A. L. Harmsen, S. Han, and A. G. Harmsen. 2007. Type I interferon signaling and B cells maintain hemopoiesis during Pneumocystis infection of the lung. J. Immunol. 178:6604-6615.
61. Taylor, D., M. Wilkison, J. Voyich, and N. Meissner. 2011. Prevention of bone marrow cell apoptosis and regulation of hematopoiesis by type I IFNs during systemic responses to pneumocystis lung infection. J. Immunol. 186:5956-5967.
62. Wilkison, M., K. Gauss, Y. Ran, S. Searles, D. Taylor, and N. Meissner. 2012. Type 1 IFNs suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection. Am. J. Pathol. 181:151-162.
63. Swain, S. D., S. J. Lee, M. C. Nussenzweig, and A. G. Harmsen. 2003. Absence of the macrophage mannose receptor in mice does not increase susceptibility to Pneumocystis carinii infection in vivo. Infect. Immun. 71:6213-6221.
64. Bolliger, A. P. 2004. Cytologic evaluation of bone marrow in rats: indications, methods, and normal morphology. Vet. Clin. Pathol. 33:58-67.
65. Harmsen, A. G. 1988. Role of alveolar macrophages in lipopolysaccharideinduced neutrophil accumulation. Infect. Immun. 56:1858-1863.
66. Schroder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferongamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75:163-189.
67. Hu, X., and L. B. Ivashkiv. 2009. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31:539-550.
68. Dufour, C., A. Corcione, J. Svahn, R. Haupt, V. Poggi, A. N. Béka'ssy, R. Scimè, A. Pistorio, and V. Pistoia. 2003. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 102:2053-2059.
69. Zeng, W., A. Miyazato, G. Chen, S. Kajigaya, N. S. Young, and J. P. Maciejewski. 2006. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood 107:167-175.
70. 1993. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-1993. A 28-year-old man with AIDS, persistent pancytopenia, and lymphoma. N. Engl. J. Med. 329:792-799.
71. Sims, J. E., and D. E. Smith. 2010. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10:89-102.
72. Watford, W. T., M. Moriguchi, A. Morinobu, and J. J. O'Shea. 2003. The biology of IL-12:coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 14:361-368.
73. Barker, B. R., D. J. Taxman, and J. P. Ting. 2011. Cross-regulation between the IL-1b/IL-18 processing inflammasome and other inflammatory cytokines. Curr. Opin. Immunol. 23:591-597.
74. Schmidt, R. L., and L. L. Lenz. 2012. Distinct licensing of IL-18 and IL-1b secretion in response to NLRP3 inflammasome activation. PLoS ONE 7:e45186.
75. van de Veerdonk, F. L., M. G. Netea, C. A. Dinarello, and L. A. Joosten. 2011. Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol. 32:110-116.
76. Lum, J. J., G. Bren, R. McClure, and A. D. Badley. 2005. Elimination of senescent neutrophils by TNF-related apoptosis-inducing [corrected] ligand. J. Immunol. 175:1232-1238.
77. Matsuyama, W., M. Yamamoto, I. Higashimoto, K. Oonakahara, M. Watanabe, K. Machida, T. Yoshimura, N. Eiraku, M. Kawabata, M. Osame, and K. Arimura. 2004. TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus.[Published retraction in 2008. Blood 112:3529.] Blood 104:184-191.
78. Amin, M. B., M. P. Abrash, E. Mezger, and G. F. Sekerak. 1990. Systemic dissemination of Pneumocystis carinii in a patient with acquired immunodeficiency syndrome. Henry Ford Hosp. Med. J. 38:68-71.
79. Corti, M., R. Pérez, M. de Tezanos, M. Cermelj, M. Candela, and R. Schtirbu. 1999. [Bone marrow involvement by Pneumocystis carinii in an AIDS patient]. Enferm. Infecc. Microbiol. Clin. 17:420-422.
80. Dennehy, K. M., and G. D. Brown. 2007. The role of the beta-glucan receptor Dectin-1 in control of fungal infection. J. Leukoc. Biol. 82:253-258.
81. Evans, S. E., P. Y. Hahn, F. McCann, T. J. Kottom, Z. V. Pavlovic', and A. H. Limper. 2005. Pneumocystis cell wall beta-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-kappaB-dependent mechanisms. Am. J. Respir. Cell Mol. Biol. 32:490-497.
82. Steele, C., L. Marrero, S. Swain, A. G. Harmsen, M. Zheng, G. D. Brown, S. Gordon, J. E. Shellito, and J. K. Kolls. 2003. Alveolar macrophage-mediated killing of Pneumocystis carinii f.sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J. Exp. Med. 198:1677-1688.
83. O'Meara, T. R., and J. A. Alspaugh. 2012. The Cryptococcus neoformans capsule: a sword and a shield. Clin. Microbiol. Rev. 25:387-408.
84. Goodridge, H. S., C. N. Reyes, C. A. Becker, T. R. Katsumoto, J. Ma, A. J. Wolf, N. Bose, A. S. Chan, A. S. Magee, M. E. Danielson, et al. 2011. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature 472:471-475.
85. Bloom, M. L., A. G. Wolk, K. L. Simon-Stoos, J. S. Bard, J. Chen, and N. S. Young. 2004. A mouse model of lymphocyte infusion-induced bone marrow failure. Exp. Hematol. 32:1163-1172.
86. Yu, J. M., R. V. Emmons, Y. Hanazono, S. Sellers, N. S. Young, and C. E. Dunbar. 1999. Expression of interferon-gamma by stromal cells inhibits murine long-term repopulating hematopoietic stem cell activity. Exp. Hematol. 27:895-903.
87. Zoumbos, N., P. Gascon, and N. Young. 1984. The function of lymphocytes in normal and suppressed hematopoiesis. Blut 48:1-9.
88. Pang, Q., S. Fagerlie, T. A. Christianson, W. Keeble, G. Faulkner, J. Diaz, R. K. Rathbun, and G. C. Bagby. 2000. The Fanconi anemia protein FANCC binds to and facilitates the activation of STAT1 by gamma interferon and hematopoietic growth factors. Mol. Cell. Biol. 20:4724-4735.
89. Alexander, W. S., R. Starr, J. E. Fenner, C. L. Scott, E. Handman, N. S. Sprigg, J. E. Corbin, A. L. Cornish, R. Darwiche, C. M. Owczarek, et al. 1999. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98:597-608.
90. Fenner, J. E., R. Starr, A. L. Cornish, J. G. Zhang, D. Metcalf, R. D. Schreiber, K. Sheehan, D. J. Hilton, W. S. Alexander, and P. J. Hertzog. 2006. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat. Immunol. 7:33-39.
91. Meissner, N., S. Swain, K. McInnerney, S. Han, and A. G. Harmsen. 2010. Type-I IFN signaling suppresses an excessive IFN-gamma response and thus prevents lung damage and chronic inflammation during Pneumocystis (PC) clearance in CD4 T cell-competent mice. Am. J. Pathol. 176:2806-2818.
92. Smyth, M. J., E. Cretney, K. Takeda, R. H. Wiltrout, L. M. Sedger, N. Kayagaki, H. Yagita, and K. Okumura. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193:661-670.
93. Kakagianni, T., N. C. Giannakoulas, E. Thanopoulou, A. Galani, S. Michalopoulou, A. Kouraklis-Symeonidis, and N. C. Zoumbos. 2006. A probable role for trailinduced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients. Leuk. Res. 30:713-721.
94. Langaas, V., S. Shahzidi, J. I. Johnsen, B. Smedsrød, and B. Sveinbjørnsson. 2001. Interferon-gamma modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res. 21(Suppl. 6A):3733-3738.
95. Meng, R. D., and W. S. El-Deiry. 2001. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferongamma. Exp. Cell Res. 262:154-169.
96. Carson, W. E., J. E. Dierksheide, S. Jabbour, M. Anghelina, P. Bouchard, G. Ku, H. Yu, H. Baumann, M. H. Shah, M. A. Cooper, et al. 2000. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood 96:1465-1473.
97. Micallef, M. J., T. Tanimoto, K. Kohno, H. Ikegami, and M. Kurimoto. 2000. Interleukin 18 induces a synergistic enhancement of interferon gamma production in mixed murine spleen cell-tumor cell cultures: role of endogenous interleukin 12. Cancer Detect. Prev. 24:234-243.
98. Robak, E., T. Robak, A. Wozniacka, M. Zak-Prelich, A. Sysa-Jedrzejowska, and H. Stepien. 2002. Proinflammatory interferon-gamma-inducing monokines (interleukin-12, interleukin-18, interleukin-15)-serum profile in patients with systemic lupus erythematosus. Eur. Cytokine Netw. 13:364-368.
99. Torre, D. 2009. Early production of gamma-interferon in clinical malaria: role of interleukin-18 and interleukin-12. Clin. Infect. Dis. 48:1481-1482.
100. Mosser, D. M., and X. Zhang. 2008. Interleukin-10:new perspectives on an old cytokine. Immunol. Rev. 226:205-218.
101. Stanley, A. C., and P. Lacy. 2010. Pathways for cytokine secretion. Physiology (Bethesda) 25:218-229.
102. Kelly, M. N., M. Zheng, S. Ruan, J. Kolls, A. D'Souza, and J. E. Shellito. 2013. Memory CD4+ T cells are required for optimal NK cell effector functions against the opportunistic fungal pathogen Pneumocystis murina. J. Immunol. 190:285-295.
103. Swann, J. B., Y. Hayakawa, N. Zerafa, K. C. Sheehan, B. Scott, R. D. Schreiber, P. Hertzog, and M. J. Smyth. 2007. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178:7540-7549.
104. Del Vecchio, M., E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini. 2007. Interleukin-12:biological properties and clinical application. Clin. Cancer Res. 13:4677-4685.
105. Masters, S. L., M. Gerlic, D. Metcalf, S. Preston, M. Pellegrini, J. A. O'Donnell, K. McArthur, T. M. Baldwin, S. Chevrier, C. J. Nowell, et al. 2012. NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity 37:1009-1023.
106. Kamga, I., S. Kahi, L. Develioglu, M. Lichtner, C. Marañón, C. Deveau, L. Meyer, C. Goujard, P. Lebon, M. Sinet, and A. Hosmalin. 2005. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J. Infect. Dis. 192:303-310.
107. Soumelis, V., I. Scott, F. Gheyas, D. Bouhour, G. Cozon, L. Cotte, L. Huang, J. A. Levy, and Y. J. Liu. 2001. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 98:906-912.
108. Soumelis, V., I. Scott, Y. J. Liu, and J. Levy. 2002. Natural type 1 interferon producing cells in HIV infection. Hum. Immunol. 63:1206-1212.
109. Sepkowitz, K. A. 2002. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin. Infect. Dis. 34:1098-1107.
110. Moses, A., J. Nelson, and G. C. Bagby, Jr. 1998. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 91:1479-1495.